Sino Biopharmaceutical Limited Financial Statements (SBMFF)
|
|
|
|
Report date
|
|
|
31.12.2021 |
31.12.2022 |
31.12.2023 |
31.12.2024 |
31.12.2025 |
|
31.12.2025 |
|
Currency
|
|
|
CNY |
CNY |
CNY |
CNY |
CNY |
|
CNY |
|
|
Revenue, bln rub |
? |
|
26 861 |
26 026 |
26 199 |
28 866 |
31 013 |
|
24 071 |
|
Operating Income, bln rub |
|
|
5 079 |
5 586 |
5 786 |
6 136 |
6 638 |
|
4 956 |
|
EBITDA, bln rub |
? |
|
19 874 |
6 691 |
6 979 |
6 109 |
7 791 |
|
5 023 |
|
Net profit, bln rub |
? |
|
14 608 |
2 544 |
2 332 |
3 500 |
2 283 |
|
3 630 |
|
|
OCF, bln rub |
? |
|
5 366 |
6 265 |
6 066 |
6 615 |
9 292 |
|
3 160 |
|
CAPEX, bln rub |
? |
|
1 894 |
1 706 |
1 704 |
960.1 |
1 703 |
|
270.8 |
|
FCF, bln rub |
? |
|
3 472 |
4 560 |
4 362 |
5 655 |
7 589 |
|
2 890 |
|
Dividend payout, bln rub
|
|
|
938.5 |
1 268 |
632.7 |
1 846 |
1 503 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
6.42% |
49.8% |
27.1% |
52.8% |
65.8% |
|
0 |
|
|
OPEX, bln rub |
|
|
17 186 |
15 953 |
15 540 |
17 394 |
18 815 |
|
14 642 |
|
Cost of production, bln rub |
|
|
5 332 |
5 796 |
4 990 |
5 336 |
5 560 |
|
4 327 |
|
R&D, bln rub |
|
|
3 747 |
4 333 |
4 473 |
5 235 |
5 715 |
|
4 443 |
|
Interest expenses, bln rub |
|
|
308.6 |
429.5 |
495.2 |
295.1 |
271.1 |
|
0.000 |
|
|
Assets, bln rub |
|
|
60 543 |
64 064 |
63 605 |
65 408 |
76 048 |
|
76 010 |
|
Net Assets, bln rub |
? |
|
30 291 |
29 747 |
30 474 |
31 961 |
30 686 |
|
30 671 |
|
Debt, bln rub |
|
|
12 118 |
13 982 |
12 580 |
9 784 |
16 078 |
|
16 070 |
|
Cash, bln rub |
|
|
15 794 |
16 922 |
14 118 |
14 597 |
22 558 |
|
22 961 |
|
Net debt, bln rub |
|
|
-3 677 |
-2 940 |
-1 538 |
-4 813 |
-6 480 |
|
-6 891 |
|
|
Ordinary share price, rub |
|
|
0.665 |
0.585 |
0.416 |
0.411 |
0.872 |
|
0.692 |
|
Number of ordinary shares, mln |
|
|
18 769 |
18 622 |
23 392 |
17 244 |
18 002 |
|
|
|
|
Market cap, bln rub |
|
|
12 481 |
10 894 |
9 731 |
7 087 |
15 698 |
|
0 |
|
EV, bln rub |
? |
|
8 805 |
7 954 |
8 193 |
2 274 |
9 218 |
|
-6 891 |
|
Book value, bln rub |
|
|
28 579 |
27 833 |
29 546 |
28 900 |
23 631 |
|
23 619 |
|
|
EPS, rub |
? |
|
0.78 |
0.14 |
0.10 |
0.20 |
0.13 |
|
|
|
FCF/share, rub |
|
|
0.19 |
0.24 |
0.19 |
0.33 |
0.42 |
|
|
|
BV/share, rub |
|
|
1.52 |
1.49 |
1.26 |
1.68 |
1.31 |
|
|
|
|
EBITDA margin, % |
? |
|
74.0% |
25.7% |
26.6% |
21.2% |
25.1% |
|
20.9% |
|
Net margin, % |
? |
|
54.4% |
9.77% |
8.90% |
12.1% |
7.36% |
|
15.1% |
|
FCF yield, % |
? |
|
27.8% |
41.9% |
44.8% |
79.8% |
48.3% |
|
0.00% |
|
ROE, % |
? |
|
48.2% |
8.55% |
7.65% |
11.0% |
7.44% |
|
11.8% |
|
ROA, % |
? |
|
24.1% |
3.97% |
3.67% |
5.35% |
3.00% |
|
4.78% |
|
|
P/E |
? |
|
0.85 |
4.28 |
4.17 |
2.03 |
6.88 |
|
0.00 |
|
P/FCF |
|
|
3.59 |
2.39 |
2.23 |
1.25 |
2.07 |
|
0.00 |
|
P/S |
? |
|
0.46 |
0.42 |
0.37 |
0.25 |
0.51 |
|
0.00 |
|
P/BV |
? |
|
0.44 |
0.39 |
0.33 |
0.25 |
0.66 |
|
0.00 |
|
EV/EBITDA |
? |
|
0.44 |
1.19 |
1.17 |
0.37 |
1.18 |
|
-1.37 |
|
Debt/EBITDA |
|
|
-0.18 |
-0.44 |
-0.22 |
-0.79 |
-0.83 |
|
-1.37 |
|
|
R&D/CAPEX, % |
|
|
197.8% |
254.0% |
262.5% |
545.2% |
335.6% |
|
1 640% |
|
|
CAPEX/Revenue, % |
|
|
7.05% |
6.55% |
6.50% |
3.33% |
5.49% |
|
1.13% |
|
| Sino Biopharmaceutical Limited shareholders |
